What's your prediction Blazer on how low these wall street mouth foaming hedge funds take down the SP before they decide to cover? We're already down to pre-partial lift MAYO news release levels.
....didn't Dr. Tefferi already show the FDA that patients taking imetelstat for MF didn't suffer from any permanent liver damage and those LFT low levels that were detectable were also reversible?
"All of Geron's chips are placed on one drug: imetelstat. Unfortunately for Geron, the pathway to success for the drug hit a roadblock in March. The U.S. Food and Drug Administration placed a full clinical hold on studies of imetelstat targeting essential thrombocythemia and multiple myeloma due to concerns about potential liver problems for patients taking the drug. A few days later, the FDA also placed a partial clinical hold on another study of imetelstat focusing on treatment of myelofibrosis that is being led by Mayo Clinic's Dr. Ayalew Tefferi.
Last month, Geron received a bit of good news as the partial clinical hold on Dr. Tefferi's study was lifted. The clinical trials sponsored by Geron itself, however, are still on hold until the biotech can show the FDA that patients taking imetelstat won't suffer from permanent liver damage.
Assuming that Geron can make a convincing argument for imetelstat, the future could be brighter than the past couple of decades. Dr. Tefferi's research found that some myelofibrosis patients taking the drug went into complete remission. By contrast, the only drug currently approved for myelofibrosis, Incyte's (NASDAQ: INCY ) Jakafi, doesn't boast that kind of efficacy.
Jakafi generated over $235 million in revenue for Incyte last year and is expected to make at least $315 million in 2014. If Geron ultimately navigates the regulatory waters successfully, imetelstat could become an even bigger winner than Jakafi. Any chances of positive earnings, though, are still years away: Geron's drug is still only in phase 2 trials."
IBB up 1.5%, GERN down another 4.78%
$2.76 GAP filled
Asterias shares distributed as per July 22 "Ex-Dividend Date"
And still we decline?
"Problem"? The firm making GERN's market has kept SP down for years. What's wrong with pure & applied market forces fur once?
As to finger pointing, given the market seems to be in a recovering mode this morning (all my biotechs are up cept fur GERN :( Yellen's loud comments on Tuesday may have been the excuse used to tear down GERN's SP by 20%, it seems more likely that the Jakafi lobby is behind all this SP manipulation. They could easily be working with some market funds and are obviously paying shills in the MPN's forum to edit out any relevant info on IMET. Who knows who they may have paid off within the FDA. The MAYO can only go so far with their partial clinical hold being lifted.
down 15% in 3 days. IBB down 4% in same time frame. This must be manipulated by hedge fund shorts. No news is usually good news.
Hedge funds made a killing again.
Wonder where are all the ambulance chasers are seeing how GERN is on the Gerney, AGAIN?
They need to launch a class action against the FDA for this frivolous hold on IMET. Enough is enough.
Irish what happened to your last post on the "Promedior PRM-151 thread"? I never read it but your handle name stayed up.
Was worried some INCY hit man may have gotten to you.
I agree with your observations but it was also the MM's fake head on Tuesday morning with the $3.09 SP, 937.700 volume spike between 9:39-9:49AM that set us up for the shorting fiesta frenzy that has followed.
He can't be shorting his own company but nothing stopping hedge funds from shorting based on likely time lines.
Upside Target Price: 4.09 Profit: 47.7% , Profit/Loss Ratio: 7.3 : 1 - Excellent for an extreme rally
Downside Target Price: 1.91 Profit: 31% , Profit/Loss Ratio: 3.4 : 1 - Good for an extreme pullback
Given the last two days of yellen bearish sentiment, odds favour upside trading 5:3. Place ur bets.